Oragenics, Inc. (NYSEAMERICAN:OGEN) Short Interest Update

Oragenics, Inc. (NYSEAMERICAN:OGEN) saw a large growth in short interest in January. As of January 30th, there was short interest totaling 524,157 shares, a growth of 806.3% from the January 15th total of 57,838 shares. Based on an average daily trading volume, of 1,798,797 shares, the short-interest ratio is currently 0.3 days. Currently, 13.7% of the shares of the stock are short sold. Currently, 13.7% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,798,797 shares, the short-interest ratio is currently 0.3 days.

Hedge Funds Weigh In On Oragenics

A number of institutional investors have recently bought and sold shares of OGEN. Bank of America Corp DE increased its stake in shares of Oragenics by 7,374.0% in the second quarter. Bank of America Corp DE now owns 15,546 shares of the company’s stock worth $59,000 after purchasing an additional 15,338 shares in the last quarter. Sabby Management LLC purchased a new stake in Oragenics in the third quarter worth about $77,000. Finally, Clear Street LLC bought a new position in shares of Oragenics during the 2nd quarter worth approximately $270,000. 18.71% of the stock is owned by institutional investors.

Oragenics Stock Up 3.4%

NYSEAMERICAN:OGEN traded up $0.02 during trading hours on Tuesday, hitting $0.72. 73,098 shares of the company were exchanged, compared to its average volume of 933,608. Oragenics has a one year low of $0.63 and a one year high of $9.60. The company has a fifty day simple moving average of $0.85 and a 200 day simple moving average of $1.07.

Oragenics (NYSEAMERICAN:OGEN) last announced its quarterly earnings results on Friday, November 7th. The company reported ($1.96) EPS for the quarter.

About Oragenics

Oragenics, Inc is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.

The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures.